Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc.  (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for the first quarter
View HTML
Toggle Summary Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
LEXINGTON, Mass. , May 10, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced the hiring of David McMullin to the newly
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 9, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will issue financial results for the quarter ended March
View HTML
Toggle Summary Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting
Data Demonstrate Statistically and Clinically Significant Activity of Topical Ocular 0.1% Reproxalap Across a Broad Array of Signs and SymptomsSafety and Tolerability Consistent with Standard of Care
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
LEXINGTON, Mass. , April 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has enrolled the first patient in a
View HTML
Toggle Summary Aldeyra Therapeutics Announces Year End 2017 Financial Results
LEXINGTON, Mass. , March 29, 2018 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced financial results for the year ended
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results
LEXINGTON, Mass. , March 22, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, will issue financial results for the year ended December
View HTML
Toggle Summary Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases
LEXINGTON, Mass. , Feb. 27, 2018 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has entered into a collaborative
View HTML
Toggle Summary Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Poster Presentations to Feature Phase 2b Allergic Conjunctivitis Results, in Addition to Activity of Reproxalap and ADX-103 in Models of Retinal Inflammation, Diabetic Macular Edema, and Dry Age-Related Macular Degeneration
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial
LEXINGTON, Mass. , Jan. 30, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinical trial of
View HTML